Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000443499 | SCV000535750 | likely benign | not specified | 2017-01-03 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Color Diagnostics, |
RCV000582700 | SCV000690594 | likely benign | Hereditary cancer-predisposing syndrome | 2017-09-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000582700 | SCV001187410 | likely benign | Hereditary cancer-predisposing syndrome | 2015-11-25 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV001040269 | SCV001203832 | likely benign | Familial adenomatous polyposis 2 | 2023-12-13 | criteria provided, single submitter | clinical testing | |
True Health Diagnostics | RCV000582700 | SCV000886691 | likely benign | Hereditary cancer-predisposing syndrome | 2018-07-16 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004539914 | SCV004773012 | likely benign | MUTYH-related disorder | 2020-02-20 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |